MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Vaxcyte Inc

Abierto

SectorSanidad

33.42 0.57

Resumen

Variación precio

24h

Actual

Mínimo

32.92

Máximo

34.42

Métricas clave

By Trading Economics

Ingresos

-34M

-137M

BPA

-1.018

Empleados

414

EBITDA

87M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+274.34% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-6.3B

3.9B

Apertura anterior

32.85

Cierre anterior

33.42

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Vaxcyte Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2025, 14:19 UTC

Principales Movimientos del Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3 sept 2024, 17:22 UTC

Principales Noticias

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Comparación entre iguales

Cambio de precio

Vaxcyte Inc previsión

Precio Objetivo

By TipRanks

274.34% repunte

Estimación a 12 Meses

Media 124.13 USD  274.34%

Máximo 160 USD

Mínimo 65 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vaxcyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

11

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

30.39 / N/ASoporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.